276 related articles for article (PubMed ID: 19457931)
1. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
[No Abstract] [Full Text] [Related]
2. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
3. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
4. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
[TBL] [Abstract][Full Text] [Related]
5. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
[TBL] [Abstract][Full Text] [Related]
6. Evolution of raltegravir resistance during therapy.
Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
[TBL] [Abstract][Full Text] [Related]
7. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
[TBL] [Abstract][Full Text] [Related]
9. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
10. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
11. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
[TBL] [Abstract][Full Text] [Related]
12. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
[TBL] [Abstract][Full Text] [Related]
13. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
Delaugerre C
Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
[TBL] [Abstract][Full Text] [Related]
14. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
[No Abstract] [Full Text] [Related]
15. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
Wirden M; Simon A; Schneider L; Tubiana R; Malet I; Ait-Mohand H; Peytavin G; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Nov; 64(5):1087-90. PubMed ID: 19717396
[TBL] [Abstract][Full Text] [Related]
16. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L
Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574
[TBL] [Abstract][Full Text] [Related]
17. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
19. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
20. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
